Patents by Inventor Eun Joung Moon

Eun Joung Moon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220135621
    Abstract: The present invention relates to a peptide consisting of the amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof and to the use thereof. The present invention is capable of effectively treating or preventing insulitis. Moreover, the present invention is capable of effectively treating or preventing type 1 diabetes.
    Type: Application
    Filed: March 5, 2020
    Publication date: May 5, 2022
    Inventors: Hae Jin KIM, Eun-Joung MOON, Young Hoon LEE
  • Patent number: 10544190
    Abstract: The present invention provides a peptide consisting of the amino acid sequence of SEQ ID NO:1 or the amino acid sequence of SEQ ID NO:2, or a pharmaceutically acceptable salt thereof and a use thereof. The present invention can inhibit the entry of beta-amyloid into the brain. In addition, the present invention can be applied more easily with respect to the suppression of the intracerebral action of beta-amyloid and thus is advantageous in having excellent applicability.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 28, 2020
    Assignee: ENSOL BIOSCIENCES INC.
    Inventors: Hae Jin Kim, Eun Joung Moon, Duk Soon Hwang
  • Publication number: 20190161517
    Abstract: The present invention provides a peptide consisting of the amino acid sequence of SEQ ID NO:1 or the amino acid sequence of SEQ ID NO:2, or a pharmaceutically acceptable salt thereof and a use thereof. The present invention can inhibit the entry of beta-amyloid into the brain. In addition, the present invention can be applied more easily with respect to the suppression of the intracerebral action of beta-amyloid and thus is advantageous in having excellent applicability.
    Type: Application
    Filed: March 24, 2017
    Publication date: May 30, 2019
    Inventors: Hae Jin KIM, Eun Joung MOON, Duk Soon HWANG
  • Patent number: 10189875
    Abstract: Provided are a peptide consisting of the amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof, and the use thereof. Cancer can be effectively prevented or treated by application of the peptide.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 29, 2019
    Assignee: ENSOL BIOSCIENCES INC.
    Inventors: Hae Jin Kim, Duk Soon Hwang, Eun Joung Moon
  • Patent number: 10167316
    Abstract: Provided are a peptide consisting of the amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof, and the use thereof. Cancer can be effectively prevented or treated by application of the peptide.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 1, 2019
    Assignee: ENSOL BIOSCIENCES INC.
    Inventors: Hae JIn Kim, Duk Soon Hwang, Eun Joung Moon
  • Publication number: 20180186834
    Abstract: This invention relates to a peptide consisting of an amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof, and to the use thereof. According to this invention, cancer can be effectively prevented or treated.
    Type: Application
    Filed: July 22, 2016
    Publication date: July 5, 2018
    Inventors: Hae Jin KIM, Duk Soon HWANG, Eun Joung MOON
  • Patent number: 8772241
    Abstract: The present invention provides a peptide represented by formula (I) of X1-Leu-X2-Leu-X3 wherein X1 represents Glu or Asp, X2 represents His, Lys or Arg, X3 represents Asp or Glu, with Glu, Asp, Leu, His, Lys and Arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof; a composition for the treatment or prevention of at least one selected from cartilage damage and arthritis, containing the same peptide or a pharmaceutically acceptable salt thereof as an active ingredient; and a composition containing the same peptide or a pharmaceutically acceptable salt thereof and TGF?1.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: July 8, 2014
    Assignee: Ensoltek Co., Ltd.
    Inventors: Hae Jin Kim, Je Wook Lee, Young Joon Kwon, Eun Joung Moon
  • Patent number: 8691749
    Abstract: The present invention provides a peptide comprising an amino acid sequence of SEQ ID NO: 1 and a pharmaceutically acceptable salt thereof effective for treating degenerative disc diseases, treating body organ fibrosis, treating cancer and/or treating glomerulosclerosis, and effective for the inhibition of TGF-beta 1 signaling.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: April 8, 2014
    Assignee: Ensoltek Co., Ltd.
    Inventors: Hae Jin Kim, Eun Joung Moon, Yang Seon Kim, Young Joon Kwon
  • Publication number: 20130109626
    Abstract: The present invention provides a peptide represented by formula (I) of X1-Leu-X2-Leu-X3 wherein X1 represents Glu or Asp, X2 represents His, Lys or Arg, X3 represents Asp or Glu, with Glu, Asp, Leu, His, Lys and Arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof; a composition for the treatment or prevention of at least one selected from cartilage damage and arthritis, containing the same peptide or a pharmaceutically acceptable salt thereof as an active ingredient; and a composition containing the same peptide or a pharmaceutically acceptable salt thereof and TGF?1.
    Type: Application
    Filed: June 22, 2011
    Publication date: May 2, 2013
    Applicant: ENSOLTEX CO., LTD.
    Inventors: Hae Jin Kim, Je Wook Lee, Young Joon Kwon, Eun Joung Moon
  • Publication number: 20120190625
    Abstract: The present invention provides a peptide comprising an amino acid sequence of SEQ ID NO: 1, a variant thereof and a pharmaceutically acceptable salt thereof. A novel peptide of the present invention, a variant thereof and a pharmaceutically acceptable salt thereof are effective for treating and/or preventing degenerative disc diseases, treating body organ fibrosis, treating cancer and/or treating glomerulosclerosis, and are effective for the inhibition of TGF-beta1 signaling.
    Type: Application
    Filed: February 12, 2010
    Publication date: July 26, 2012
    Applicant: ENSOLTEK CO., LTD.
    Inventors: Hae Jin Kim, Eun Joung Moon, Yang Seon Kim, Young Joon Kwon